Year-end Sale % OFF 
Abstract
Wu Wei Zi is the dried fruit of Schisandra chinensis (Turcz.) Baill. or Schisandra sphenanthera Rehd. et Wils. (family Magnoliaceae). As a homology of medicine and food, it has been widely used in China for thousands of years, to tonify the kidney, and ameliorate neurological, cardiovascular, liver, and gastrointestinal disorders. As its increasing health benefits and pharmacological value, many literatures have reported that the combination of Wu Wei Zi in patients has led to fluctuations in the blood level of the combined drug. Therefore, it is extremely important to evaluate its safety concern such as drug-drug interactions (DDIs) when patients are under the poly-therapeutic conditions. This review summarized the effects of Wu Wei Zi extract and its major lignan components on cytochrome P450 and P-glycoprotein activities, the change of which could induce metabolic DDIs. Our review also elaborated on the differences of the major lignan components of the two Schisandra species, as well as the absorption, distribution, metabolism, and elimination of the major lignans. In conclusion, these results would enhance our understanding of the DDI mechanisms involving Wu Wei Zi, and may potentially untangle some differing and conflicting results in the future.
Highlights
In recent years, the researchers paid more attention to the review of the botany, phytochemistry, chemical composition, in-depth in vivo pharmacological study, and clinical application of North Wu Wei Zi or South Wu Wei Zi (Szopa et al, 2017; Li et al, 2018; Huang et al, 2021), and only one review covered both North Wu Wei Zi and South Wu Wei Zi (Yang et al, 2022)
SCH and gomisin C (Gom C) are defined as the quality markers of North Wu Wei Zi and South Wu Wei Zi, respectively, according to the Chinese pharmacopoeia, where the SCH content is required to be above 0.40% (North Wu Wei Zi), and Gom C content should be higher than above 0.20% (South Wu Wei Zi)
Over the past few years, there have been many reports concerning the pharmacokinetic interactions involving the components of Wu Wei Zi in the form of herb extract, herb decoction, or herb preparation (Feng et al, 2017)
Summary
The researchers paid more attention to the review of the botany, phytochemistry, chemical composition, in-depth in vivo pharmacological study, and clinical application of North Wu Wei Zi or South Wu Wei Zi (Szopa et al, 2017; Li et al, 2018; Huang et al, 2021), and only one review covered both North Wu Wei Zi and South Wu Wei Zi (Yang et al, 2022). Little information was presented about their metabolic DDIs. In this review, we mainly focus on the main components of North Wu Wei Zi and South Wu Wei Zi, and identified CYPand P-gp-interfering effects of the schisandra lignans, in order to better understand the quality control and potential DDIs of Wu Wei Zi products. By creating a full picture of the potential impacts of Wu Wei Zi, this review might facilitate investigations on DDIs for new chemical products and traditional Chinese medicines
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
